PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. [electronic resource]
Producer: 20170911Description: 3607-12 p. digitalISSN:- 1476-5594
- Animals
- Breast Neoplasms -- drug therapy
- Cell Line, Tumor
- Cell Survival -- drug effects
- Class I Phosphatidylinositol 3-Kinases
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Lapatinib
- Mammary Neoplasms, Experimental -- drug therapy
- Mice, Knockout
- Molecular Targeted Therapy -- methods
- PTEN Phosphohydrolase -- deficiency
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphoinositide-3 Kinase Inhibitors
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinazolines -- pharmacology
- Receptor, ErbB-2 -- antagonists & inhibitors
- Signal Transduction -- drug effects
- Thiazoles -- pharmacology
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.